Composite quantitative knee structure metrics predict the development of accelerated knee osteoarthritis:data from the osteoarthritis initiative by Harkey, Matthew S. et al.
RESEARCH ARTICLE Open Access
Composite quantitative knee structure
metrics predict the development of
accelerated knee osteoarthritis: data from
the osteoarthritis initiative
Matthew S. Harkey1,2* , Julie E. Davis3, Lori Lyn Price4,5, Robert J. Ward6, James W. MacKay7, Charles B. Eaton8,
Grace H. Lo9,10, Mary F. Barbe11, Ming Zhang1,12, Jincheng Pang13, Alina C. Stout14, Bing Lu15,
Timothy E. McAlindon1 and Jeffrey B. Driban1
Abstract
Background: We aimed to determine if composite structural measures of knee osteoarthritis (KOA) progression on
magnetic resonance (MR) imaging can predict the radiographic onset of accelerated knee osteoarthritis.
Methods: We used data from a nested case-control study among participants from the Osteoarthritis Initiative
without radiographic KOA at baseline. Participants were separated into three groups based on radiographic disease
progression over 4 years: 1) accelerated (Kellgren-Lawrence grades [KL] 0/1 to 3/4), 2) typical (increase in KL,
excluding accelerated osteoarthritis), or 3) no KOA (no change in KL). We assessed tibiofemoral cartilage damage
(four regions: medial/lateral tibia/femur), bone marrow lesion (BML) volume (four regions: medial/lateral tibia/femur),
and whole knee effusion-synovitis volume on 3 T MR images with semi-automated programs. We calculated two
MR-based composite scores. Cumulative damage was the sum of standardized cartilage damage. Disease activity
was the sum of standardized volumes of effusion-synovitis and BMLs. We focused on annual images from 2 years
before to 2 years after radiographic onset (or a matched time for those without knee osteoarthritis). To determine
between group differences in the composite metrics at all time points, we used generalized linear mixed models
with group (3 levels) and time (up to 5 levels). For our prognostic analysis, we used multinomial logistic regression
models to determine if one-year worsening in each composite metric change associated with future accelerated
knee osteoarthritis (odds ratios [OR] based on units of 1 standard deviation of change).
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Results: Prior to disease onset, the accelerated KOA group had greater average disease activity compared to the
typical and no KOA groups and this persisted up to 2 years after disease onset. During a pre-radiographic disease
period, the odds of developing accelerated KOA were greater in people with worsening disease activity [versus
typical KOA OR (95% confidence interval [CI]): 1.58 (1.08 to 2.33); versus no KOA: 2.39 (1.55 to 3.71)] or cumulative
damage [versus typical KOA: 1.69 (1.14 to 2.51); versus no KOA: 2.11 (1.41 to 3.16)].
Conclusions: MR-based disease activity and cumulative damage metrics may be prognostic markers to help
identify people at risk for accelerated onset and progression of knee osteoarthritis.
Keywords: Magnetic resonance imaging, Cartilage, Bone marrow lesions, Effusion, Synovitis
Background
Knee osteoarthritis is typically considered a gradually progres-
sive disease that is a leading cause of physical disability [1].
However, at least 20% of people who develop knee osteoarth-
ritis will experience a more painful, debilitating, and acceler-
ated form of knee osteoarthritis. Accelerated knee
osteoarthritis is defined as a person progressing from a normal
joint on radiographs to advanced-stage radiographic disease
within 4 years, and oftentimes this progression occurs within
a single year [2, 3]. People prior to the radiographic develop-
ment of accelerated knee osteoarthritis are more likely to re-
port frequent knee pain and present with decreased physical
function (e.g., slower walking and chair-stand pace) compared
to those who develop a typical, gradual onset of knee osteo-
arthritis [2]. Additionally, people that develop accelerated knee
osteoarthritis are more likely to receive pharmacological treat-
ments and knee replacements than people who develop typ-
ical knee osteoarthritis [4, 5]. Therefore, developing prognostic
methods to detect early manifestations of the disease will be
key to identifying who is at high-risk for the radiographic de-
velopment of accelerated knee osteoarthritis.
The development of accelerated knee osteoarthritis is
characterized by extensive pre-radiographic structural
pathology detected with magnetic resonance (MR) im-
aging when compared to people that experience the typ-
ical, gradual onset of knee osteoarthritis [6]. Greater
increases in effusion-synovitis and bone marrow lesion
(BML) volume [7, 8], as well as a more rapid decline in
articular cartilage thickness are structural alterations ob-
served in people prior to x-ray evidence of accelerated
knee osteoarthritis compared to typical knee osteoarth-
ritis development [8, 9]. However, traditional quantita-
tive MR-based assessments of individual structural
pathologies fail to help classify people who will develop
accelerated knee osteoarthritis better than models with
only clinical measures [10]. Novel approaches that com-
bine the structural burden across multiple knee regions
and pathologies may efficiently quantify total structural
burden of knee osteoarthritis to account for the multi-
factorial etiology of the disease and help identify people
at risk for accelerated knee osteoarthritis development.
We recently deployed an extensive, iterative process to
create and validate a “whole-knee” MR-based composite
metric based on cartilage damage, bone marrow lesions
(BMLs), and effusion-synovitis [11]. Out of 12 candidate
composite metrics, two emerged as superior to the
others. These novel composite metrics conceptualize
knee osteoarthritis progression as two constructs. First,
the disease activity metric combines multiple regions of
BML volume and effusion-synovitis volume that reflects
the transient fluctuations of knee osteoarthritis path-
ology and is related to knee pain. Second, the cumulative
damage metric combines cartilage damage throughout
the entire tibiofemoral joint and represents the accumu-
lation of joint damage throughout the course of disease
[11]. These two composite metrics offer a novel way to
conceptualize and define knee osteoarthritis progression
that is consistent with frameworks used in other diseases
(e.g., systemic lupus erythematosus, rheumatoid arth-
ritis) [12, 13].
It is unclear how these composite metrics differ prior
to and following the radiographic onset of accelerated
knee osteoarthritis when compared to people that de-
velop typical knee osteoarthritis or remain with no knee
osteoarthritis. Additionally, it is unclear if longitudinal
change in these composite metrics prior to the radio-
graphic onset of disease is prognostic of future develop-
ment of accelerated knee osteoarthritis. Therefore, our
first aim was to determine if disease activity or cumula-
tive damage differed between an accelerated or typical
knee osteoarthritis group prior to and following radio-
graphic disease development, as well as compared to a
no knee osteoarthritis group over the same period. Our
second aim was to determine if one-year change in dis-
ease activity or cumulative damage prior to the develop-
ment of disease was associated with the future
development of accelerated knee osteoarthritis. We
hypothesize that there will be greater disease activity and
cumulative damage prior to the onset of accelerated
knee osteoarthritis, which will persist up to 2 years after
disease onset. Additionally, the people exhibiting greater
worsening of disease activity or cumulative damage over
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a one-year period before radiographic disease onset will
be more likely to develop accelerated knee osteoarthritis.
Methods
Study design
We conducted a secondary longitudinal analysis on a
nested case-control study that was designed to
characterize people that developed either accelerated or
typical knee osteoarthritis or remained without knee
osteoarthritis within the initial 4 years of the Osteoarth-
ritis Initiative (OAI). Within the OAI, 4796 people with
or at risk for symptomatic knee osteoarthritis were en-
rolled at four clinical sites from February 2004 to May
2006: Memorial Hospital of Rhode Island, Ohio State
University, University of Pittsburgh, and University of
Maryland and Johns Hopkins [14]. Each of the OAI clin-
ical sites, as well as the coordinating center at the Uni-
versity of California, San Francisco received approval
from their respective institutional review boards. Prior
to enrollment in the OAI, all participants provided in-
formed consent.
Participant selection
We focused on people with no evidence of radiographic
knee osteoarthritis (i.e., Kellgren-Lawrence [KL] grade 0/
1) at the OAI baseline visit. We used the bilateral KL
grades from the central OAI readers who scored the
weight-bearing, fixed-flexion posteroanterior knee radio-
graphs [3]. The knee radiographs were monitored at
each visit during the initial 4 years of the OAI to define
disease progression (files: kXR_SQ_BU##_SAS [versions
0.6, 1.6, 3.5, 5.5, and 6.3]) [14]. We identified three
groups based on the amount of disease progression during
the initial 4 years of the OAI: 1) accelerated knee osteo-
arthritis: progressed to KL 3/4 in 4 years (n = 125); 2) typ-
ical knee osteoarthritis: any other KL grade increase in 4
years (n = 187); 3) no knee osteoarthritis: KL grade
remained the same over 4 years (n = 1325) [3]. Figure 1
provides examples of the radiographic disease progression
used to define each knee osteoarthritis group. People in
the typical and no knee osteoarthritis groups were
matched by sex to people in the accelerated knee osteo-
arthritis group (i.e., 125 people per group). Figure 1 pro-
vides an example of the radiographic definition that
defines group enrollment.
Defining the index knee
The index knee in the accelerated knee osteoarthritis
group was defined as the first knee that progressed to
KL3/4 in 4 years. The index knee in the typical knee
osteoarthritis group was defined as the first knee to in-
crease in KL grade in 4 years. Since neither knee pro-
gressed in the no knee osteoarthritis group remained the
same over 4 years, the index knee in this group was
matched to the index limb of their matched participant
in the accelerated knee osteoarthritis group.
Defining the index visit and study observation period
The index visit in the accelerated and typical knee osteo-
arthritis groups was defined as the visit in which the per-
son’s index knee met the accelerated or typical knee
osteoarthritis definition, respectively. The index visit in
Fig. 1 Examples of Radiographic Changes that Define the Knee Osteoarthritis Groups and the Study Observation Period. This figure provides
examples of Kellgren-Lawrence (KL) grades overtime in each of the knee OA groups. We focused on visits up to 2 years prior to and up to 2
years after the index visit
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the no knee osteoarthritis group was matched to the
index visit of their matched participant in the acceler-
ated knee osteoarthritis group. Figure 1 provides a
graphical representation of how the index visit was de-
fined for each group. For this study, we focused on the
yearly OAI visits up to 2 years before and up to 2 years
after a person’s index visit (Fig. 1).
MR imaging methodology
MR acquisition
Each OAI site used identical Siemens Trio 3-Tesla MR
systems and followed the specifications in the OAI Im-
aging Protocol [15]. Cartilage damage index (CDI) was
assessed using a 3-dimensional dual-echo steady-state
sequence. A sagittal intermediate-weighted, turbo spin
echo, fat-suppressed MR sequence was used to assess
effusion-synovitis bone marrow lesion and volume. These
sequences have been described in detail elsewhere [15].
Quantifying cartilage damage index (CDI)
A single reader (JED) used a custom semi-automated
program to quantify tibiofemoral CDI, a valid measure
of cartilage thickness (Fig. 2) [16, 17]. Briefly, the reader
would measure cartilage thickness at 36 informative
locations in the medial/lateral femur/tibia (i.e., 9 each re-
gion) that were automatically located by the semi-
automated program based on the width of the knee.
These 36 locations were considered informative because
this is where people with knee osteoarthritis are most
likely to develop cartilage defects [17]. The semi-
automated program produces a CDI value for all four
tibiofemoral regions (medial/lateral femur/tibia). The
study principal investigator (JBD) reviewed all CDI mea-
surements and has exhibited excellent intra-reader reli-
ability with this technique (ICC3,1 = 0.86 to 0.99).
Quantifying BML volume
A single reader (ACS) used a semi-automated program
to assess BML volume (Fig. 2) [18, 19]. Based on crude
bone boundaries identified by the reader, the program
automatically identified the precise bone boundaries and
segmented areas of high signal intensity (e.g., BML). To
rule out areas of high signal intensity that were not con-
sidered a BML, we defined a BML as: 1) originating < 10
mm from the articular surface [20]; 2) needing to be
present on more than one MR slice. BML volume was
quantified within all four tibiofemoral regions (medial/
lateral femur/tibia). The study principal investigator
reviewed all BML volume measurements has exhibited
excellent intra-reader reliability (ICC3,1 = 0.91).
Quantifying effusion-Synovitis volume
A single reader (JBD) used a semi-automatic program to
measure whole joint knee effusion-synovitis (Fig. 2) [6, 21].
After the reader identified the proximal patellar border and
the fibular head apex on a MR slice in the middle of the
joint, the software automatically segmented effusion-
synovitis within these manual set boundaries. After manu-
ally excluding areas of high intensity not considered
effusion-synovitis, the semi-automatic program determined
the effusion-synovitis volume throughout the entire knee
joint. The study principal investigator reviewed all effusion-
Fig. 2 Composite Structural Metrics that Conceptualize Knee Osteoarthritis Progression as the Combination of Cumulative Damage and Disease
Activity. Parsimonious semi-automated programs were used to individually assess cartilage damage index, bone marrow lesion volume, and
effusion-synovitis. Cumulative damage is the sum of standardized cartilage damage (four regions: medial/lateral tibia/femur). Disease activity is
the sum of the standardized volumes of effusion-synovitis (single volumetric measure) and BML (four regions: medial/lateral tibia/femur)
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synovitis volume measurements and has exhibited demon-
strated excellent intra-reader reliability (ICC3,1 = 0.96).
Normalizing individual MR measures used in composite
metrics
To calculate the composite MR metrics, we used 9 MR-
based measures: CDI (4 regions =medial/lateral femur/
tibia), BML volume (4 regions =medial/lateral femur/
tibia), and effusion-synovitis volume (1 region = whole
joint). Prior to combining the individual MR measures
into the composite metrics, each of the 9 measures was
normalized to knee size (i.e., multiplying each measure
to the ratio of the person’s bone width to the average
bone width of 500 knees previously measured within the
OAI). Next, we standardized the normalized measures
with the means and standard deviations of the entire
group at the earliest study time point (i.e., 2 years prior
to the index visit): (individual normalized measure –
whole group mean of normalized measure)/whole group
standard deviation of normalized measure. This
standardization approach has two purposes: 1) puts all
MR-based measure on the same scale, 2) enhances the
interpretability of the measures.
Creating composite metrics of MR-based knee structure
Since the MR-based measures are all on the same standard-
ized scale, we are able to combine the measures to calculate
the composite metrics: 1) disease activity: sum of the stan-
dardized BML volume for all four tibiofemoral regions plus
the whole-joint effusion-synovitis volume; 2) cumulative
damage: sum of the standardized CDI for all four tibiofe-
moral regions. To ensure that a larger value for disease activ-
ity and cumulative damage indicated worse knee pathology,
we multiplied the cumulative damage metric by − 1. Add-
itionally, interpretability of the composite metrics is im-
proved as both disease activity and cumulative damage are
interpreted as the number of standard deviations away from
the overall group mean at the earliest stage of disease.
Clinical data
Body mass index (BMI), age, race, days with limited ac-
tivity in the prior month, frequent knee pain within the
past month (i.e., yes or no), overall global rating, pain
medication (i.e., yes or no), and Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC)
pain were acquired at each OAI visit. The data are pub-
licly available (Files: allclinical0#; version 0.2.2, 1.2.1,
3.2.1, 5.2.1, 6.2.1) [14].
Statistical analysis
Longitudinal differences in cumulative damage and disease
activity
To determine between group differences at all time
points for disease activity and cumulative damage, we
used 2 generalized linear mixed models with group (3
levels) and time (up to 5 levels) as independent variables.
In the presence of a significant group-by-time interaction, we
used three post hoc comparisons at each time point to deter-
mine which groups differed at each individual time point. We
adjusted for sex (i.e., matching variable) and factors related to
missing MR data at the next visit (i.e., age, BMI, injury, frequent
knee pain, days with limited activity in prior month, overall glo-
bal rating, and WOMAC pain). We assessed model diagnostics
on the cumulative damage and disease activity analyses and re-
ran the analyses excluding people with potentially influential
data (i.e., large Cook’s D value or Cook’s D covariance parame-
ters). We conducted a sensitivity analysis that only included in-
dividuals with KL 0 at the OAI baseline visit (accelerated, n=
42; typical, n=71; no knee osteoarthritis, n=92; no matching).
Association between one-year change in composite metrics
and future onset of accelerated knee osteoarthritis
We calculated a one-year change in cumulative damage
and disease activity from two to 1 year prior to the index
visit (i.e., during a pre-radiographic phase of disease).
We used two multinomial logistic regressions models to
determine if a one-year change in disease activity or cu-
mulative damage was associated with the future develop-
ment of accelerated knee osteoarthritis compared to the
development of typical or no knee osteoarthritis. Odds
ratios are reported as increased odds for developing ac-
celerated knee osteoarthritis per standard deviation for
one-year change in composite metric. Using covariates
from a similar prognostic osteoarthritis imaging analysis,
we adjusted for sex, race, and baseline age, BMI, KL
grade, WOMAC pain, and use of pain medication [22].
Results
Longitudinal differences in cumulative damage and
disease activity
Table 1 provides the baseline characteristics for each
group and demographic comparisons between the acceler-
ated, typical, and no knee osteoarthritis groups. Figure 3
depicts the disease activity and cumulative damage over
time in people with accelerated, typical, or no knee osteo-
arthritis. Starting at 1 year prior and continuing to at least 2
years after the index visit, the accelerated knee osteoarthritis
group presented with greater disease activity compared to
the typical and no knee osteoarthritis groups (Fig. 3). At the
index visit, the mean disease activity for people that develop
accelerated knee osteoarthritis is 6.1 standard deviations
greater than the overall group mean compared with the
other two groups that are only 0.1 (typical knee osteoarth-
ritis) and− 0.3 (no knee osteoarthritis) standard deviations
away from the overall group mean.
Starting after the index visit, the accelerated knee osteo-
arthritis group had worse cumulative damage compared to
the typical and no knee osteoarthritis groups (Fig. 3). The
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cumulative damage in the people with accelerated knee
osteoarthritis increases with each successive year, with the
greatest cumulative damage occurring at 2 years after the
index visit (i.e., mean cumulative damage = 1.5 standard
deviations).
The typical and no knee osteoarthritis groups were not sta-
tistically significantly different at any time points for disease
activity and cumulative damage (Fig. 3). Omitting influential
data (e.g., based on a large Cook’s D) did not change the pat-
terns of longitudinal alterations in disease activity and cumu-
lative damage. In our sensitivity analysis that only included
individuals with KL 0 at OAI baseline, we confirmed the sta-
tistically significant results in the primary analysis.
Association between one-year change in composite
metrics and future onset of accelerated knee
osteoarthritis
Table 2 demonstrates the means and standard deviations
of the one-year change in disease activity and cumulative
damage from two to one years prior to the index visit for
participants that develop accelerated, typical, or no knee
osteoarthritis. Greater worsening of disease activity and cu-
mulative damage from two to one years prior to the index
visit is associated with the development of accelerated knee
osteoarthritis compared to both typical and no knee osteo-
arthritis development. Specifically, for every standard devi-
ation of disease activity worsening there is a 58 and 139%
increase in the odds of developing accelerated knee osteo-
arthritis compared to typical and no knee osteoarthritis, re-
spectively (Table 2). For every standard deviation of
cumulative damage worsening there is a 69 and 111% in-
crease in the odds of developing accelerated knee osteoarth-
ritis compared to typical and no knee osteoarthritis,
respectively (Table 2). In our sensitivity analysis that only in-
cluded individuals with KL 0 at OAI baseline, we confirmed
the statistically significant results in the primary analysis.
Discussion
Composite structural metrics of disease activity and cu-
mulative damage offer a parsimonious and novel strategy
Table 1 Group Baseline Characteristics
Knee Osteoarthritis Group
Variables Accelerated Typical No
[(means (SD); except where noted) (n = 125) (n = 125) (n = 125) P*
Females, n(%) 79 (63%) 79 (63%) 79 (63%) 1.00
Age (years) 62.5 (8.5)* 58.4 (8.4) 57.3 (8.2) < 0.001
Body mass index (kg/m2) 29.7 (4.6)* 28.1 (4.4) 26.9 (4.4) < 0.001
Index knee KL Grade = 0, n(%) 42 (34%)* 71 (57%)^ 92 (74%) < 0.001
WOMAC pain (0–20; ↑score = ↑pain) 2.6 (3.3) 1.6 (2.1) 1.4 (2.0) 0.08
Overall Global Rating (0–10, ↑score = ↑effect) 1.7 (1.9)* 1.1 (1.5) 0.8 (1.1) < 0.001
Days with limited activity in prior month 3.2 (7.3)^ 1.7 (4.8) 1.4 (4.3) 0.03
P values are for the overall group main effect from a one-way analysis of variance (for continuous measures) or chi-square tests (for dichotomous variables). * =
P < 0.017 versus typical knee osteoarthritis and no knee osteoarthritis, ^ = P < 0.017 versus no knee osteoarthritis
Fig. 3 Differences in Composite Structural Metrics in Individuals with Accelerated Compared to Typical and No Knee Osteoarthritis. A. Disease
Activity. B. Cumulative Damage. Statistically siginificant differences in accelerated compared to typical(*) or no (^) knee osteoarthritis. Adjusted for
sex and factors related to missing magnetic resonance data at the next visit (i.e., age, body mass index, injury, frequent knee pain, days with
limited activity in prior month, overall global rating, and WOMAC pain)
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to conceptualize the onset and progression of knee
osteoarthritis, especially accelerated knee osteoarthritis.
Disease activity, which is a dynamic metric of structural
changes, is greater in people that develop accelerated
knee osteoarthritis starting at 1 year prior to radio-
graphic onset and up to at least 2 years following their
index visit. Additionally, at all visits after the index visit,
cumulative damage is greater in people that developed
accelerated knee osteoarthritis compared to typical or
no knee osteoarthritis. Prior to the onset of disease, an
annual change of both cumulative damage and disease
activity were associated with future radiographic devel-
opment of accelerated knee osteoarthritis compared to
typical and no knee osteoarthritis development. These
results agree with previous reports that people who de-
velop accelerated knee osteoarthritis present with a dif-
ferent pattern of pre-radiographic structural changes
compared to people that develop typical knee osteoarth-
ritis [6–9, 23]. Conceptualizing accelerated knee osteo-
arthritis development as two different constructs (i.e.,
cumulative damage and disease activity) using quantita-
tive composite metrics may provide a robust way to
structurally define the onset and development of this de-
bilitating subset of knee osteoarthritis.
We intentionally used widely available imaging tech-
niques and relatively simple analyses to create quantita-
tive composite knee structure metrics to overcome some
of the technical challenges of traditional quantitative and
semi-quantitative knee osteoarthritis structural assess-
ments. First, traditional quantitative knee osteoarthritis
structural assessments tend to primarily focus on articu-
lar cartilage and often require 2 to 6 h per knee to seg-
ment cartilage [24, 25]. In contrast, our composite
metrics combine cartilage damage with BML and
effusion-synovitis volume to conceptualize knee osteo-
arthritis as a disease of multi-tissue failure [26]. Add-
itionally, the individual components of the composite
metrics are assessed using time-efficient techniques that
need minimal researcher effort and can process the
entire knee within minutes. Second, while current semi-
quantitative scoring systems provide an assessment of
whole joint disease, these systems yield over 100 ordinal
or dichotomous scores that cannot be combined into
composite scores [27]. A Rasch analysis of a common
semi-quantitative knee osteoarthritis scoring system
“raised important questions about summating ordinal
scores from multiple anatomical sites” because it “does
not always produce a valid summed score for a unidi-
mensional scale” [28]. Thus, these composite structural
metrics of cumulative damage and disease activity are: 1)
time-efficient, 2) offer a whole knee approach to define
disease progression, and 3) improve interpretability of
whole-joint disease burden.
Disease activity is a composite of the extent of BMLs and
effusion-synovitis throughout the joint, which are both inde-
pendently associated with joint symptoms [11, 19, 29–31].
At a year prior to the development of accelerated knee osteo-
arthritis, people present with elevated disease activity when
compared to people that will eventually develop typical knee
osteoarthritis or remain with no knee osteoarthritis. This ele-
vation in disease activity peaks at the index visit and persists
for at least 2 years after the onset of disease (Fig. 3). This ele-
vation in disease activity is consistent with prior findings of
greater pre-radiographic pain and functional limitations in
people that go on to develop accelerated knee osteoarthritis
compared to those that develop typical knee osteoarthritis
[2]. These findings agree with previous reports that separ-
ately report greater BML and effusion-synovitis volume in
people prior to accelerated knee osteoarthritis development
[7, 8]. However, since people likely experience both BMLs
and effusion-synovitis, a composite metric that combines
these structural features provides a better estimation of the
whole-joint disease burden that defines a patient’s current
state of disease and symptoms compared to each individual
feature.
Cumulative damage reflects the accumulation of dam-
age attributable to knee osteoarthritis over the course of
the disease and relates to radiographic knee
Table 2 Longitudinal Change in Cumulative Damage and Disease Activity From Two to One Year Prior to the Index Visit is
Associated with Accelerated Knee Osteoarthritis (AKOA) Development
Knee Osteoarthritis (KOA) Group OR (95% Confidence Interval)a
OR per unit of SDb
1-Year Change in Composite Metrics Accelerated
(n = 87)
Mean (SD)
Typical
(n = 64)
Mean (SD)
No
(n = 96)
Mean (SD)
Accelerated vs Typical KOA (REF) Accelerated vs No KOA (REF)
Cumulative Damage 0.34 (0.70) 0.10 (0.44) 0.01 (0.55) 1.69
(1.14–2.51)^
2.11
(1.41–3.16)^
Disease Activity 1.49 (3.20) 0.61 (1.72) 0.06 (1.52) 1.58
(1.08–2.33)^
2.39
(1.55–3.71)^
OR odds ratio,
aAdjusted for age, BMI, sex, race, WOMAC pain, KL grade, and pain medication at the visit 2 years prior to the index visit
b Odds ratios are reported as increased odds for developing accelerated knee osteoarthritis per entire group standard deviation for one-year change in
cumulative damage (i.e., 0.60) and disease activity (i.e., 2.37)
^Statistically significant (p< 0.05)
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osteoarthritis severity. Our findings provide construct
validity of the cumulative damage metric because cumu-
lative damage fails to differentiate accelerated and typical
knee osteoarthritis until after the index visit, which is
when radiographic changes to joint space occur. How-
ever, an annual change in cumulative damage over a
pre-radiographic disease period is associated with the fu-
ture onset of accelerated disease. Specifically, for every
standard deviation of cumulative damage worsening
prior to disease development participants were at a 69
and 111% chance of developing accelerated knee osteo-
arthritis compared to typical and no knee osteoarthritis,
respectively. This highlights that people with accelerated
knee osteoarthritis are accumulating damage faster than
people with typical knee osteoarthritis even during this
pre-radiographic phase when x-rays are too insensitive
to monitor disease progression. The cumulative damage
metric offers a parsimonious strategy to conceptualize
cartilage damage throughout the joint rather than rely-
ing on at least four different regional metrics. While
these results provide an overall estimation of cumulative
damage throughout the tibiofemoral joint, previous re-
ports have demonstrated that starting at the index visit
the people with accelerated knee osteoarthritis had
greater cartilage damage in the medial and lateral tibia
as well as the medial femur than those with typical or no
knee osteoarthritis [8]. Additionally, people that develop
accelerated knee osteoarthritis present with a more dif-
fuse spatial pattern of cartilage change throughout the
tibiofemoral compartment compared to those that de-
velop typical knee osteoarthritis [9]. Hence, an advantage
to using cumulative damage in analyses is that it effi-
ciently describes the damage associated with accelerated
knee osteoarthritis without the need for numerous
analyses.
While this study highlights the utility of using com-
posite metrics to define the burden and progression of
structural disease prior to the development of acceler-
ated knee osteoarthritis, there are some limitations that
need to be mentioned. Our composite metrics use a
combination of whole joint articular cartilage damage,
BML volume, and effusion-synovitis volume to quantify
metrics of cumulative damage and disease activity; how-
ever, there are other joint structures that play a role in
the onset and progression of knee osteoarthritis. Add-
itionally, our structural metrics focused solely on the
tibiofemoral joint and we acknowledge that not includ-
ing the patellofemoral compartment is a limitation. Fu-
ture studies are needed to develop parsimonious,
quantitative methods for quantifying outcomes that as-
sess other relevant joint structures (e.g., meniscus, ten-
dons, and ligaments) that can be incorporated into the
composite structural metrics. Furthermore, future stud-
ies of accelerated knee osteoarthritis should also
consider the patellofemoral compartment as 66–75% of
people in all three groups present with MR evidence of
patellofemoral osteoarthritis [7].The sample size of this
study was relatively small since we focused on the role
of these composite metrics at predicting the onset of ac-
celerated knee osteoarthritis. Future studies are needed
to utilize these techniques in a larger study to better dis-
cern how these composite metrics can be used to iden-
tify other subsets or phenotypes of knee osteoarthritis.
Conclusions
In conclusion, composite knee osteoarthritis metrics that
conceptualize structural disease progression as cumula-
tive damage or disease activity are elevated in people
prior to and following the onset and progression of ac-
celerated knee osteoarthritis. Additionally, an annual
change in both composite metrics during a pre-
radiographic stage of disease predicts the accelerated on-
set of disease. These composite metrics of knee osteo-
arthritis structural damage offer a more time-efficient
interpretable method of quantifying whole-joint disease
burden when compared to traditional techniques.
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